NYSEAMERICAN:NBY NovaBay Pharmaceuticals (NBY) Stock Price, News & Analysis → The 2024 Gold Rush: Unleashing Market Potential (From Priority Gold) (Ad) Free NBY Stock Alerts $0.08 -0.01 (-11.06%) (As of 05/10/2024 ET) Add Compare Share Share Today's Range$0.08▼$0.0950-Day Range N/A52-Week Range$0.07▼$1.28Volume1.84 million shsAverage Volume3.27 million shsMarket Capitalization$338,484.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort Interest Get NovaBay Pharmaceuticals alerts: Email Address NovaBay Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.38% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.56Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($2.54) to ($0.55) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.77 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for NovaBay Pharmaceuticals.Read more about NovaBay Pharmaceuticals' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.38% of the float of NovaBay Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverNovaBay Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in NovaBay Pharmaceuticals has recently decreased by 34.17%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldNovaBay Pharmaceuticals does not currently pay a dividend.Dividend GrowthNovaBay Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NBY. Previous Next 2.0 News and Social Media Coverage News SentimentNovaBay Pharmaceuticals has a news sentiment score of 0.56. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for NovaBay Pharmaceuticals this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for NBY on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added NovaBay Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NovaBay Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.30% of the stock of NovaBay Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 1.34% of the stock of NovaBay Pharmaceuticals is held by institutions.Read more about NovaBay Pharmaceuticals' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for NovaBay Pharmaceuticals are expected to grow in the coming year, from ($2.54) to ($0.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of NovaBay Pharmaceuticals is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of NovaBay Pharmaceuticals is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNovaBay Pharmaceuticals has a P/B Ratio of 0.05. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Priority GoldThe 2024 Gold Rush: Unleashing Market PotentialWelcome to the financial rollercoaster of 2024, where inflation is persistent, stock markets are overinflated and volatile, global conflicts are intensifying, and the national debt is reaching new heights.Get your free information kit NOW, before it's too late. About NovaBay Pharmaceuticals Stock (NYSEAMERICAN:NBY)NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands. The company also provides dermatological solutions to address skincare concerns comprising keratosis pilaris, rosacea and eczema, anti-aging, hyperhidrosis, excessive hair, and acne under the DERMAdoctor brand. It sells its products through traditional and digital beauty retailers and distributors, as well as online. The company was formerly known as NovaCal Pharmaceuticals, Inc. and changed its name to NovaBay Pharmaceuticals, Inc. in February 2007. NovaBay Pharmaceuticals, Inc. was incorporated in 2000 and is headquartered in Emeryville, California.Read More NBY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NBY Stock News HeadlinesMay 12, 2024 | americanbankingnews.comNovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) Short Interest Down 34.2% in AprilMay 8, 2024 | markets.businessinsider.comNovaBay Pharmaceuticals is about to announce earnings — here's what Wall Street expectsMay 12, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. May 4, 2024 | americanbankingnews.comNovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Share Price Crosses Above 50-Day Moving Average of $0.00April 17, 2024 | finance.yahoo.comNovaBay Pharmaceuticals Reports Preliminary Eyecare and Wound Care Revenue Increased 13% for the First Quarter of 2024 on Lower Sales and Marketing ExpensesApril 17, 2024 | markets.businessinsider.comBuy Rating Maintained for NovaBay Pharma Amid Strategic Refocus and Resilient Revenue PerformanceMarch 27, 2024 | finance.yahoo.comNovaBay Pharmaceuticals, Inc. (AMEX:NBY) Q4 2023 Earnings Call TranscriptMarch 27, 2024 | finance.yahoo.comQ4 2023 NovaBay Pharmaceuticals Inc Earnings CallMay 12, 2024 | Colonial Metals (Ad)Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. March 15, 2024 | barrons.comNovaBay Pharmaceuticals Inc.March 14, 2024 | markets.businessinsider.comNovaBay Pharmaceuticals To Sell DERMAdoctor Skincare Business - Quick FactsMarch 13, 2024 | markets.businessinsider.comNovaBay Pharmaceuticals and Eyenovia to Co-Promote Prescription Ophthalmic Products to U.S. Eyecare ProfessionalsFebruary 26, 2024 | finance.yahoo.comNovaBay Pharmaceuticals, Inc. (NBY)January 30, 2024 | finance.yahoo.comNovaBay Pharmaceuticals Reports 64% Year-Over-Year Growth in Avenova Unit Subscription-Based SalesJanuary 29, 2024 | msn.comWhy ZIM Integrated Shipping Services Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving PremarketJanuary 9, 2024 | finance.yahoo.comNovaBay Pharmaceuticals and Sonoma Pharmaceuticals Agree to Market Avenova-branded Products in the European Union Through Sonoma’s Extensive Distributor NetworkDecember 6, 2023 | finance.yahoo.comNovaBay Pharmaceuticals Partners with Woo University to Educate Eyecare Professionals on the Use of Amniotic MembranesNovember 12, 2023 | finance.yahoo.comNovaBay Pharmaceuticals, Inc. (AMEX:NBY) Q3 2023 Earnings Call TranscriptNovember 9, 2023 | benzinga.comRecap: NovaBay Pharmaceuticals Q3 EarningsNovember 9, 2023 | finance.yahoo.comNovaBay Pharmaceuticals Reports Third Quarter 2023 Financial ResultsNovember 2, 2023 | finance.yahoo.comNovaBay Pharmaceuticals to Hold Third Quarter 2023 Conference Call on November 9, 2023October 21, 2023 | thestreet.comNovaBay Pharmaceuticals: CEO InterviewOctober 11, 2023 | finance.yahoo.comNovaBay Pharmaceuticals Expands Physician Dispensed Sales Channel with New Avenova ProgramsOctober 2, 2023 | finance.yahoo.comNovaBay Pharmaceuticals to Present at the Dawson James Small Cap Growth ConferenceSeptember 11, 2023 | marketwatch.comNovaBay Pharma Shares Rise 42% After Deal With BioStem TechnologiesSeptember 11, 2023 | markets.businessinsider.comNovaBay Pharma Agrees With BioStem To Commercialize Amniotic Tissue Allograft As Avenova AllograftSeptember 11, 2023 | benzinga.comWhy NovaBay Pharmaceuticals Stock Is Blasting HigherSee More Headlines Receive NBY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NovaBay Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/26/2024Today5/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNYSEAMERICAN:NBY CUSIPN/A CIK1389545 Webnovabay.com Phone(510) 899-8800Fax510-474-1577Employees24Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($9.9465) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-10,610,000.00 Net Margins-79.70% Pretax Margin-79.70% Return on Equity-146.20% Return on Assets-69.63% Debt Debt-to-Equity RatioN/A Current Ratio1.85 Quick Ratio1.25 Sales & Book Value Annual Sales$14.40 million Price / Sales0.02 Cash FlowN/A Price / Cash FlowN/A Book Value$1.53 per share Price / Book0.05Miscellaneous Outstanding Shares4,210,000Free Float4,160,000Market Cap$338,484.00 OptionableNot Optionable Beta2.82 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMr. Justin M. Hall Esq. (Age 46)President, CEO, General Counsel, Chief Compliance Officer, Corporate Secretary & Director Comp: $364.15kMr. Tommy Law (Age 39)Controller, Interim CFO & Treasurer Comp: $155.48kKey CompetitorsPolarityTENASDAQ:PTEIQAsterias BiotherapeuticsNYSEAMERICAN:AST9 Meters BiopharmaNASDAQ:NMTRHemispherx BioPharmaNYSEAMERICAN:HEBSmart for LifeNASDAQ:SMFLView All Competitors NBY Stock Analysis - Frequently Asked Questions How have NBY shares performed in 2024? NovaBay Pharmaceuticals' stock was trading at $0.1802 on January 1st, 2024. Since then, NBY stock has decreased by 55.4% and is now trading at $0.0804. View the best growth stocks for 2024 here. Are investors shorting NovaBay Pharmaceuticals? NovaBay Pharmaceuticals saw a drop in short interest in the month of April. As of April 30th, there was short interest totaling 137,000 shares, a drop of 34.2% from the April 15th total of 208,100 shares. Based on an average trading volume of 2,410,000 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.4% of the company's stock are short sold. View NovaBay Pharmaceuticals' Short Interest. How were NovaBay Pharmaceuticals' earnings last quarter? NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) released its quarterly earnings data on Tuesday, March, 26th. The biopharmaceutical company reported ($0.95) earnings per share (EPS) for the quarter. The biopharmaceutical company had revenue of $3.73 million for the quarter. NovaBay Pharmaceuticals had a negative trailing twelve-month return on equity of 146.20% and a negative net margin of 79.70%. When did NovaBay Pharmaceuticals' stock split? Shares of NovaBay Pharmaceuticals reverse split before market open on Wednesday, November 16th 2022. The 1-35 reverse split was announced on Wednesday, November 16th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 16th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What other stocks do shareholders of NovaBay Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other NovaBay Pharmaceuticals investors own include Aeterna Zentaris (AEZS), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), Bionano Genomics (BNGO), Heat Biologics (HTBX), iBio (IBIO), Matinas BioPharma (MTNB), Novan (NOVN), ADMA Biologics (ADMA) and Vaxart (VXRT). How do I buy shares of NovaBay Pharmaceuticals? Shares of NBY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NYSEAMERICAN:NBY) was last updated on 5/12/2024 by MarketBeat.com Staff From Our PartnersTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsCEO of Biggest AI Chipmaker Just Dropped a Bombshell…Banyan Hill PublishingThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsGold Set to EXPLODE!Gold Safe Exchange[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICElon to Transform U.S. Economy? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NovaBay Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
